Marie Schoumacher
Research Subjects
Marie Schoumacher has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Ana Giménez-Capitán
Laboratory of Oncology, Pangaea Oncology, Quiron Dexeus University Hospital, 08028, Barcelona, Spain
1 shared publicationAndrés-Felipe Cardona
Clinical and Translational Oncology Group, Institute of Oncology, Fundacion Santa Fe de Bogotá, Bogotá, 110111, Colombia
1 shared publication- Carles Codony-Servat
Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Barcelona, Spain
1 shared publication - Cristina Teixidó
Molecular Biology CORE, Hospital Clínic de Barcelona, Barcelona 08036, Spain
1 shared publication Frédérique Cantero
Institut de Recherches Internationales Servier, 92284, Suresnes, France
1 shared publication- Jordi Bertran-Alamillo
Hospital Universitario Dexeus, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 18 April 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-14
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M or other acquired mutations are sensitive to the Aurora B (AURKB) inhibitors barasertib and S49076. Phospho-histone H3 (pH3), a major product of AURKB, is increased in most resistant cells and treatment with AURKB inhibitors reduces the levels of pH3, triggering G1/S arrest and polyploidy. Senescence is subsequently induced in cells with acquired mutations while, in their absence, polyploidy is followed by cell death. Finally, in NSCLC patients, pH3 levels are increased after progression on EGFR TKIs and high pH3 baseline correlates with shorter survival. Our results reveal that AURKB activation is associated with acquired resistance to EGFR TKIs, and that AURKB constitutes a potential target in NSCLC progressing to anti-EGFR therapy and not carrying resistance mutations.
- 18 April 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-14
Open AccessAURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M or other acquired mutations are sensitive to the Aurora B (AURKB) inhibitors barasertib and S49076. Phospho-histone H3 (pH3), a major product of AURKB, is increased in most resistant cells and treatment with AURKB inhibitors reduces the levels of pH3, triggering G1/S arrest and polyploidy. Senescence is subsequently induced in cells with acquired mutations while, in their absence, polyploidy is followed by cell death. Finally, in NSCLC patients, pH3 levels are increased after progression on EGFR TKIs and high pH3 baseline correlates with shorter survival. Our results reveal that AURKB activation is associated with acquired resistance to EGFR TKIs, and that AURKB constitutes a potential target in NSCLC progressing to anti-EGFR therapy and not carrying resistance mutations.